AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01630005 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: talk therapy
Description: Psychotherapy
Study NCT00262002 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar (pneumococcal polysaccharide serotypes 4, 9V, 14, 18C, 19F, 23F & 6B conjugated to the CRM197)
Description: Prevnar was administered IM in the anterolateral area of the left thigh.
Study NCT00262002 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MMR (Measles, Mumps and Rubella vaccine)
Description: MMR at 12 month of age, administered in the left arm.
Study NCT00262002 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaPHibIPV (Diphtheria, Tetanus, acellular Pertussis, H. Influenzae type b, Inactivated Poliovaccine)
Description: DTaPHibIPV at 2, 3, 4 months of age, administered IM in the anterolateral area of the left thigh.
Study NCT01045863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03382792 Cohort 1
Description: First cohort for: Single oral ascending dose of PF-03382792, formulated in solution.
Study NCT00262002 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Menjugate (Men C conjugated vaccine)
Description: Menjugate was injected IM in the anterolateral area of the right thigh.
Study NCT00927225 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine 0.2%, 50 mL
Study NCT00927225 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Study NCT01017757 — intervention group
Intervention type: PROCEDURE
Intervention: High-resolution CT scanning
Description: High-resolution CT scanning
Study NCT03039608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: combination of local steroid injection（triamcinolone ）with oral steroid administration（prednisone）
Description: local steroid injection and oral steroid
Study NCT03039608 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral steroid administration（prednisone）
Description: oral steroid
Study NCT01181947 — intervention group
Intervention type: DEVICE
Intervention: TEVAR
Description: Thoracic endovascular aneurysm repair
Study NCT01045863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03382792 Cohort 2
Description: Second cohort for: Single oral ascending dose of PF-03382792, formulated in solution.
Study NCT01045863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03382792
Description: Optional cohort 3: Single oral ascending dose of PF-03382792, formulated in solution.
Study NCT01045863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Food Effect cohort
Description: Single oral dose, cross-over to determine effect of food on PF-03382792 pharmacokinetics. Dose will be decided after reviewing data from the ascending dose portion.
Study NCT01045863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSF cohort
Description: Single oral dose of PF-03382792 formulated in solution. Dose will be decided after reviewing data from the ascending dose portion.
Study NCT02968823 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Licorice
Description: ExtractumLiquiritiaeFluidum, 1 g diluted in 30cc water, gargle the solution for 60 seconds without swallowing it starting preoperatively, 3 times a day until post-operative day 3
Study NCT02968823 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sugar water
Description: Sugar gargle: Sirupus Simplex (sugar 5 g) diluted in 30cc water, gargle the solution for 60 seconds without swallowing it starting preoperatively, 3 times a day until post-operative day 3
Study NCT02713971 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gamepad system
Description: Patients executed a set of tailored exercises including the control of weight-shift and body posture during static (e.g. upright sitting and standing), quasi-dynamic (e.g. sit-to-stand and gait initiation) and dynamic tasks (e.g. getting on a step, straight-line walking, walking with turns and over obstacles). Participants executed the tasks using Gamepad system which provided patients with visual and auditory feedback about their performances and assigned a score at the end of each exercise. The physiotherapist progressively adjusted training complexity by changing the reference values, including more difficult taks, changing the perceptive context, and/or including a dual-task.
Study NCT02713971 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physiotherapy
Description: A set of tailored exercises was defined by the clinical staff following current guidelines for physiotherapy in Parkinson's disease. In particular, stretching, joint mobilization, and balance and gait exercises were provided to participants, without any instrumentation producing biofeedback or external cues.
Study NCT03765398 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR Cognitive-motor-balance training
Description: The participant will play four of the six balance board games Table tilt, Tightrope, Soccer, Balance bubble, Light Run and Basic Step (each game is max 1.5 minutes). Each game will be superimposed with any 3 of the 6 cognitive tasks (word list generation consisting of verbal fluency (VF) and category fluency (CF), digit recall (DR), analogies (AN), mental arithmetic (MA), repeated letter (RL). The cognitive tasks will be randomized making sure that all the cognitive tasks are played with all the games. The cognitive and balance board game scores will be noted on the scoring sheet for each session. A total 10 minutes rest interval between every sub-session will be mandatorily provided.
Study NCT01382498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium dobesilate (Doxium)
Description: 500 mg, Tablet, Daily, 3 months
Study NCT01382498 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drug
Description: Similar to the that of the Experimental arm, Daily, Three months
Study NCT03232710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosiqing
Description: Aripiprazole Orally disintegrating tablets 10mg
Study NCT03232710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abilify
Description: Aripiprazol orodispersible tablets 10mg
Study NCT03176901 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction
Description: This experimental arm presents the actual Mindfulness-Based Stress Reduction program as developed in the late seventies and early eighties in its original eight week format
Study NCT03176901 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Enhancement Program
Description: This active comparison arm presents the official Health Enhancement Program in its eight week format as developed by MacCoon in 2009.
Study NCT04735783 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo breakfast
Description: Participants will consume a very low-energy, placebo breakfast meal, but will be unaware of its near complete absence of energy until the end of the study.
Study NCT04735783 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Typical whole-food breakfast
Description: Participants will consume a typical whole-food breakfast meal, equating to 20% of estimated energy requirements.
Study NCT04735783 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Water-only control
Description: Participants will consume a volume of plain water to match the water content of the very low-energy placebo breakfast and the typical whole-food breakfast.
Study NCT01542554 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low glycaemic index diet
Description: Diabetic subjects will be given dietary advice with emphasis on low glycaemic index diet
Study NCT01542554 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual diabetic diet
Description: Diabetic subjects will be given dietary advice without mention about glycaemic index
Study NCT00706771 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium bicarbonate
Description: Sodium bicarbonate: loading dose of 0.5 mmol/Kg and then continuous infusion of 0.2 mmol/Kg/hr
Study NCT00706771 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium chloride
Description: 0.9% sodium chloride: loading dose of 0.5 mmol/Kg and then continuous infusion of 0.2 mmol/Kg/hr
Study NCT05611541 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet therapy, Progressive Muscle Relaxation training, Progressive Muscle Relaxation group
Description: The group that received Progressive Muscle Relaxation training and applied progressive muscle relaxation for 8 weeks.
Study NCT05611541 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The group who received diet therapy and practiced their daily activities.
Description: The group who received diet therapy and practiced their daily activities.
Study NCT04127071 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided Needle Aspiration Procedure
Description: The intervention under investigation utilizes an ultrasound-guided needle to less invasively drain an abscess.
Study NCT04127071 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Incision and Drainage (I&D)
Description: The current standard procedure to drain an abscess of purulent material.
Study NCT02166476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem-Vaborbactam
Description: Meropenem-vaborbactam
Study NCT02166476 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piperacillin-Tazobactam
Description: Piperacillin-tazobactam
Study NCT02166476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: Levofloxacin
Study NCT02166476 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin
Description: Levofloxacin
Study NCT02166476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: Saline
Study NCT02166476 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Saline
Study NCT03067363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOR107
Description: MOR107 solution for injection
Study NCT03067363 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for injection manufactured to match MOR107 solution for injection
Study NCT03067363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low sodium diet
Description: Diet designed to restrict sodium intake to 40 mmol/day
Study NCT03067363 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Low sodium diet
Description: Diet designed to restrict sodium intake to 40 mmol/day
Study NCT02250768 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: 2ng/ml of GM-CSF supplemented into culture media
Study NCT02820064 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: duodenal biopsy during gastroduodenal endoscopy
Description: Patients for who and esophagogastroduodenoscopy in order to diagnose is performed. 8 duodenal biopsy specimens will be removed.
Study NCT04111900 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep/Circadian Friendly
Description: This intervention attempts to improve sleep and prevent circadian rhythm dysregulation among patients admitted to the medical intensive care unit (MICU). Patients within his arm will be asked to try to keep their TV off and limit their telephone use from 10pm-7am, as well as limit the amount of visitors in their room as much as possible between those hours. Patients will also be offered ear plugs and eye masks if they wish to use at night to aid in helping them sleep, if deemed medically safe to do so. Additionally nurses will be asked to bathe patients either before 10pm or after 7am, to limit their conversations in the patient's room at night, and try as much as possible to limit blood draws and waking patients during those hours as is medically safe. Nurses will also be instructed to lower the blinds in the room at 10 pm and raise them up at 7am to help with patients sleep/wake cycle.
Study NCT04843410 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hand-foot exercise
Description: The experimental group will be taught a regular exercise program for 15 minutes twice a day. The sensory exercise ball required for exercise will be given to the patients by the researcher. In addition, visual training material will be provided for the exercise program so that the patient can repeat the training at any time to ensure the permanence of the patient education. The standard care protocol of the clinic will be applied to the control group.
Study NCT04843410 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: The routine care
Description: Education about chemotherapy-associated peripheral neuropathy risk factors, why it develops and its management
Study NCT01606319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: 15 mg/kg every 6 hours as needed
Study NCT01606319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: 9.4 mg/kg every 6 hours as needed
Study NCT04513977 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Geriatric Oncology Supportive Clinic
Description: Patients will undergo Comprehensive Geriatric Assessment with subsequent tailored intervention based on deficits identified. Comprehensive palliative assessment for any symptom burden and symptommatic treatment will be done as well.
Study NCT02603705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone extended-release
Study NCT00867100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 700 mg IV
Description: single SC or IV dose in healthy subjects (Part A) and subjects with moderate to severe psoriasis (Part B).
Study NCT00867100 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 350 mg SC
Description: single SC or IV dose in healthy subjects (Part A) and subjects with moderate to severe psoriasis (Part B).
Study NCT00867100 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single SC or IV dose in healthy subjects (Part A) and subjects with moderate to severe psoriasis (Part B).
Study NCT00867100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 140 mg SC
Description: single SC or IV dose in healthy subjects (Part A) and subjects with moderate to severe psoriasis (Part B).
Study NCT02585297 — intervention group
Intervention type: OTHER
Intervention: no intervention
Study NCT04952363 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A vertical vibration platform PowerVibe Zen Pro 5900
Description: Subjects received the interventions twice a week for 8 weeks. HFCWO+WBVT group received additional 30 minutes WBVT treatment. In every WBVT session, three rounds of 3 minutes of vibration (amplitude: 2 mm; frequency: 20 Hz) were provided, with a 60-second rest between rounds.
Study NCT04952363 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HFCWO
Description: Subjects received the interventions twice a week for 8 weeks. The HFCWO was delivered by a respiratory therapist using a percussive vest at 10-13 Hz oscillating frequency and at a pressure setting of 2 cm H2O. The treatment duration was 25 minutes, and the participants remained in a sitting position.
Study NCT04952363 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFCWO
Description: Subjects received the interventions twice a week for 8 weeks. The HFCWO was delivered by a respiratory therapist using a percussive vest at 10-13 Hz oscillating frequency and at a pressure setting of 2 cm H2O. The treatment duration was 25 minutes, and the participants remained in a sitting position.
Study NCT03664206 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRS, conventional TMS and treshold tracking TMS
Description: Using~* two MagStim 200 magnetic stimulator and a figure-of-eightc double 70 mm coil~* SPECIAL MR Spectroscopy sequence~In addition, each group will undergo neurological examination
Study NCT03462043 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: ND0612
Description: s.c. infused
Study NCT03462043 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: CLES
Description: Carbidopa-Levodopa Enteral Suspension.
Study NCT02838784 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Artacent Human Amniotic Membrane
Description: Double layer dehydrated amnion product
Study NCT02838784 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Off loading with a cast walker, non-adherent dressings, debridement and moisture retentive dressings
Study NCT02484664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: We will perform a pilot clinical trial to investigate the safety and tolerability of celecoxib therapy as a single agent for patients with LAM. LAM subjects who are not taking everolimus or rapamycin will be treated with celecoxib at 200mg PO QD for 6 months. They will be monitored for respiratory function and angiomyolipoma size. At the end of the 6 month period, celecoxib will be discontinued, and subjects will be monitored for another 6 months.
Study NCT02350088 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: probiotics
Description: probiotics
Study NCT02350088 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT02435056 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IEPR Approach
Description: Adoption of Interactive Electronic Patient Record (IEPR) that consists of the following clinically-relevant main components:~* Minimum Data Set for supporting the diagnosis~* Electronic Diary with associated alerting system for monitoring the patient during the follow-up period~* Second opinion system for improving the management
Study NCT02560623 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT02560623 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood sample
Study NCT02560623 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Procedure
Description: Undergo endoscopy
Study NCT02560623 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Swallowable Sponge Cell Sampling Device
Description: Undergo swallowable sponge cell sampling assessment
Study NCT00946127 — intervention group
Intervention type: PROCEDURE
Intervention: Ventriculoperitoneal Shunt Placement
Description: In the subjects who choose this arm, at the start of study- CSF (Cerebrospinal fluid ) will be shunted to peritoneum by placing a ventriculoperitoneal shunt catheter with or without shunt valves or anti-siphon device.
Study NCT00946127 — intervention group
Intervention type: PROCEDURE
Intervention: Endoscopic Third Ventriculostomy(ETV)
Description: Patients who choose to undergo ETV arm would undergo a ventriculostomy at the start of study.
Study NCT03957902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetylsalicylic acid
Description: Different dosage effect over platelet COX enzymes, non- neoplastic and neoplastic colonic tissues used as biomarkers of clinical efficacy in CRC chemoprevention
Study NCT00099177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibandronate [Bondronat]
Description: 6mg iv on days 1-3, and 50mg po from day 22 to week 24
Study NCT00099177 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: zoledronic acid
Description: 4mg iv on day 1, and every 3-4 weeks
Study NCT00038870 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic Cell Activated Lymphocyte
Study NCT04787614 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT02452255 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fenofibrate
Description: Fenofibrate by mouth given daily throughout hospitalization for up to 12 months
Study NCT02452255 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo by mouth given daily throughout hospitalization for up to 12 months
Study NCT02452255 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: Propranolol by mouth given daily throughout hospitalization for up to 12 months
Study NCT03457844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib is followed Day 1 to day 14 by 7 days off treatment in a 21-day cycle） and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
Study NCT02182830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin low dose
Description: starting dose 10mg; forced titration after 4 weeks 25mg dose
Study NCT02182830 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: starting dose 10mg; forced titration after 4 weeks 25mg dose
Study NCT02182830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin high dose
Description: starting dose 10mg; forced titration after 4 weeks 25mg dose
Study NCT04959292 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: arthroscopy
Description: arthroscopy
Study NCT01924104 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low molecular weight heparin
Description: 2500 mIU/day, subcutaneously
Study NCT01924104 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low dose aspirin
Description: 75 mg/day, orally
Study NCT01924104 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin & aspirin
Description: Aspirin (70 mg/day, orally) \& heparin (40 mg/day, subcutaneously)